Seeking Alpha

Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company...

Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company expressed confidence about the outlook for Phase III trials of its Multikine immunotherapy treatment for head and neck cancer. The company also said it plans to increase the number of patient recruitment centers for the trials to at least 50, comapred with a current 36.
Comments (3)
  • ice9baby
    , contributor
    Comment (1) | Send Message
     
    Smooth moove ExLax!
    30 Nov 2012, 10:06 PM Reply Like
  • harrifred
    , contributor
    Comments (2) | Send Message
     
    I am a novelist (http://bit.ly/WzMm2a) and serious investor specializing in developmental drug companies like CVM. I've been following CVM for a number of years, and have attended the last five annual meetings (the company is local) which are informal affairs held at the company lab in the Baltimore suburbs. In my view, the key issue holding the stock down is that it will take 2-3 years to determine whether Multikine is effective on head and neck cancer. I don't know when the countdown started, but I believe the market sees no need to urgently accumulate the stock at this time. Add to that the unique nature of Multikine as a treatment, which makes its prospects much more speculative. The upside is that any indication of a positive Phase III outcome is likely to cause the stock to explode overnight without upside limit, because Multikine (if effective) will immediately be applied to a range of other cancers. Look at it this way: for the price of a Powerball ticket, you can currently buy almost five shares, at much better odds.
    30 Nov 2012, 10:16 PM Reply Like
  • plinck
    , contributor
    Comments (3) | Send Message
     
    As a shareholder and recovering head and neck cancer patient, this news is extremely encouraging. I only wish I could have been a part of the study - I believe the Multikine treatment would have resulted in a far superior recovery in my case. Good luck Mr.Kersten on your continuing journey.
    1 Dec 2012, 06:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs